Also known as: vitamins
Moleculin said its MIRACLE Phase 2B/3 AML trial is nearing first unblinding, with blinded CRc above 40% and CR around 30%. The first 45-subject readout is expected before June 30, 2026.
NewAmsterdam Pharma said regulatory decisions on obicetrapib in Europe, the UK and Switzerland remain expected in 2H26. PREVAIL interim analysis is planned for 4Q2026, with a result expected in 1Q2027.
The FDA approved AstraZeneca’s Saphnelo Pen for once-weekly self-administration in adults with systemic lupus erythematosus. Approval was based on Phase III TULIP-SC results showing reduced disease activity versus placebo.
Additional phase 2 data showed alixorexton sustained improvements in disease severity, cognition and fatigue in narcolepsy type 1 through weeks 12-13. The oral orexin 2 receptor agonist was generally well tolerated, with no serious treatment-emergent adverse events reported.
Trastuzumab deruxtecan is moving into earlier treatment lines for HER2-positive metastatic breast cancer, demonstrating superior efficacy over standard regimens and prompting reconsideration of long-standing treatment sequences.
Enlicitide decanoate demonstrated efficacy in reducing LDL cholesterol levels compared to placebo in patients with atherosclerotic cardiovascular disease history or risk, according to phase 3 CORALreef Lipids trial data.
A systematic review and meta-analysis demonstrates that semaglutide significantly reduces major adverse cardiovascular events in adults with type 2 diabetes, with particular benefits for nonfatal myocardial infarction and stroke.
Systematic review identifies shared molecular signatures in brain and blood for major depressive disorder, while separate study finds brain-enriched circRNA can predict SSRI treatment response.
A secondary analysis of the SOUL trial shows oral semaglutide significantly lowers heart failure-related events in type 2 diabetes patients with preexisting heart failure, particularly those with preserved ejection fraction, without increasing serious adverse events.
With semaglutide and tirzepatide shortages resolved, the FDA is cracking down on compounded GLP-1 medications. Concerns emerge over 33 unique compounded formulations with limited safety data and nonstandard delivery methods.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07780669 |
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07780656 |
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07780643 |
A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07780604 |
A SINGLE CENTER, 5-PART STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF GAL-101 SALT IN HEALTHY ADULT AND ELDERLY PARTICIPANTS |
COMPLETED | PHASE1 |
| NCT07780344 |
MRI Parameters as Biomarkers in Cystic Fibrosis (FEMPTO) |
NOT_YET_RECRUITING | NA |
| NCT07779980 |
Phase 1 Clinical Study of MWN110 Injection in Healthy Participants and Overweight or Obese Participants |
NOT_YET_RECRUITING | PHASE1 |
| NCT07779616 |
Study of PTC844 in Participants With Active Rheumatoid Arthritis |
NOT_YET_RECRUITING | PHASE2 |
| NCT07779252 |
A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between the Eyebrows |
NOT_YET_RECRUITING | PHASE3 |
| NCT07778836 |
A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia |
RECRUITING | PHASE3 |
| NCT07778693 |
Phase 3 Study of MWN109 Injection in Participants With Overweight or Obesity |
NOT_YET_RECRUITING | PHASE3 |
